What is Organogenesis Holdings Inc.'s (ORGO) StockRank?

MoatMap's StockRank for Organogenesis Holdings Inc. (ORGO) is 31/100, with a Sell signal. This is a composite score combining Quality (54), Value (55), and Momentum (11) factor ranks across MoatMap's 20,000+ stock universe.

Does Organogenesis Holdings Inc. have an economic moat?

Organogenesis Holdings Inc. (ORGO) has a Quality factor score of 54/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Organogenesis Holdings Inc. a buy, hold, or sell?

MoatMap's current signal for Organogenesis Holdings Inc. (ORGO) is Sell, based on a StockRank of 31/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Organogenesis Holdings Inc. in?

Organogenesis Holdings Inc. (ORGO) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ORGO

SELLREMOVE

Organogenesis Holdings Inc. · Healthcare · United States · $309M · Avg Vol: $3M/d

StockRank

P/E (TTM)

—

ROE

0.7%

D/E

0.2x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Small-cap wound care player with volatile earnings and no alignment with our 18-month macro themes.

COMPANY DESCRIPTION

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on developing, manufacturing, and commercializing advanced wound care and surgical biologics products. Its competitive advantage stems from proprietary, clinically proven bioengineered tissue technologies and a strong sales force serving the growing market for chronic and complex wounds. The company is a key innovator in the field of tissue regeneration.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	450.9M	433.1M	482.0M	563.0M	7.7%
EPS	—	0.12	0.04	-0.01	0.16	10.1%
Shares	—	131.6M	132.0M	126.5M	127.7M	-3.0%
Debt	70.8M	123.8M	119.4M	43.3M	82.1M	3.8%
Equity	—	265.7M	278.7M	385.3M	433.9M	17.8%
Op CF	—	24.9M	30.9M	14.2M	-10.3M	-24.4%
Inv CF	—	-33.9M	-24.4M	-10.0M	-14.2M	—
Fin CF	—	-2.2M	-5.5M	27.6M	-17.4M	—

PRICE (1Y)+1.2%

SMA 50SMA 200

$2.44

RSI (14)

57.3

52W High

$7.08

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

11.2%76.7

ROE

0.7%46.2

GP/Assets

63.5%91.6

Op. Margin

-174.7%14.4

FCF/Assets

3.5%64.0

Piotroski

25.5

Int. Cover

—N/A

D/E Ratio

0.19x54.2

Current Ratio

3.53x59.2

Value

P/E (TTM)

—N/A

EV/EBITDA

11.9x58.4

P/FCF

14.6x69.6

P/B

1.3x76.4

P/S

0.6x90.5

Div Yield

—N/A

Momentum

52W High %

34%8.5

RS 6M

-65%16.8

SMA 50/200

0.66x3.6

EPS Rev 4W

-19.6%2.9

EPS Rev 12W

—N/A

EPS Improve

-129%3.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$309M

P/E (Forward)

-8.9x

Gross Margin

73.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ORGO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ORGO	Organogenesis Holdings Inc.(you)	$309M	31	SELL
CL.CN	Cresco Labs Inc.	$293M	31	SELL
TKNO	Alpha Teknova, Inc.	$272M	32	SELL
EOLS	Evolus, Inc.	$432M	32	SELL
VREO.CN	Vireo Growth Inc.	$532M	28	SELL
AKBA	Akebia Therapeutics, Inc.	$299M	18	STRONG SELL
ESPR	Esperion Therapeutics, Inc.	$814M	30	SELL
DERM	Journey Medical Corporation	$180M	19	STRONG SELL
LFCR	Lifecore Biomedical, Inc.	$207M	10	STRONG SELL
CWEB.TO	Charlotte's Web Holdings, Inc.	$74M	30	SELL

Peer medians: ROE -23.7% · P/E 25.2x · Gross margin 44.3%

Organogenesis Holdings Inc. (ORGO) — Stock Score Summary

Organogenesis Holdings Inc. (ORGO) has a MoatMap StockRank of 31/100 based on Quality (54/100), Value (55/100), and Momentum (11/100) factor scores. The current signal is SELL. Small-cap wound care player with volatile earnings and no alignment with our 18-month macro themes.

Key Financial Metrics

Price	$2.44
Market Cap	$309M
P/E (Forward)	-8.93
Price/Book	1.29
Return on Equity	0.7%
Return on Invested Capital	11.2%
Debt/Equity	18.58
Gross Margin	73.9%
Operating Margin	-174.7%
Revenue Growth	-57.1%
Free Cash Flow	$21M

Organogenesis Holdings Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Organogenesis Holdings Inc.’s (ORGO) StockRank?: MoatMap’s StockRank for Organogenesis Holdings Inc. (ORGO) is 31/100, with a Sell signal. It is a composite of Quality (54), Value (55), and Momentum (11) factor ranks across MoatMap’s 20,000+ stock universe.
Does Organogenesis Holdings Inc. have an economic moat?: Organogenesis Holdings Inc. (ORGO) has a Quality factor score of 54/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Organogenesis Holdings Inc. a buy, hold, or sell?: MoatMap’s current signal for Organogenesis Holdings Inc. (ORGO) is Sell, based on a StockRank of 31/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Organogenesis Holdings Inc. in?: Organogenesis Holdings Inc. (ORGO) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).